Back to Search
Start Over
Conditional Survival in Patients with Chronic Myeloid Leukemia in Chronic Phase in the Era of Tyrosine Kinase Inhibitors
- Source :
- Cancer, vol 122, iss 2
- Publication Year :
- 2015
-
Abstract
- BackgroundTyrosine kinase inhibitors (TKIs) significantly improve survival in patients with chronic myeloid leukemia in chronic phase (CML-CP). Conditional probability provides survival information in patients who have already survived for a specific period of time after treatment.MethodsCumulative response and survival data from 6 consecutive frontline TKI clinical trials were analyzed. Conditional probability was calculated for failure-free survival (FFS), transformation-free survival (TFS), event-free survival (EFS), and overall survival (OS) according to depth of response within 1 year of the initiation of TKIs, including complete cytogenetic response, major molecular response, and molecular response with a 4-log or 4.5-log reduction.ResultsA total of 483 patients with a median follow-up of 99.4 months from the initiation of treatment with TKIs were analyzed. Conditional probabilities of FFS, TFS, EFS, and OS for 1 additional year for patients alive after 12 months of therapy ranged from 92.0% to 99.1%, 98.5% to 100%, 96.2% to 99.6%, and 96.8% to 99.7%, respectively. Conditional FFS for 1 additional year did not improve with a deeper response each year. Conditional probabilities of TFS, EFS, and OS for 1 additional year were maintained at >95% during the period.ConclusionsIn the era of TKIs, patients with chronic myeloid leukemia in chronic phase who survived for a certain number of years maintained excellent clinical outcomes in each age group. Cancer 2016;122:238-248. © 2015 American Cancer Society.
- Subjects :
- Myeloid
Male
Dasatinib
Severity of Illness Index
tyrosine kinase inhibitors
80 and over
Prospective Studies
Chronic
Cancer
Randomized Controlled Trials as Topic
Aged, 80 and over
Leukemia
conditional survival
response
Age Factors
Hematology
Middle Aged
Treatment Outcome
6.1 Pharmaceuticals
Leukemia, Myeloid, Chronic-Phase
Public Health and Health Services
Imatinib Mesylate
Female
Drug
Adult
Adolescent
Clinical Trials and Supportive Activities
Oncology and Carcinogenesis
Article
Disease-Free Survival
Drug Administration Schedule
Dose-Response Relationship
Young Adult
Sex Factors
chronic myeloid leukemia
Clinical Research
Predictive Value of Tests
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Humans
Oncology & Carcinogenesis
Protein Kinase Inhibitors
Aged
Analysis of Variance
Dose-Response Relationship, Drug
Evaluation of treatments and therapeutic interventions
Survival Analysis
Good Health and Well Being
Multivariate Analysis
Chronic-Phase
BCR-ABL Positive
Myelogenous
Subjects
Details
- Language :
- English
- Database :
- OpenAIRE
- Journal :
- Cancer, vol 122, iss 2
- Accession number :
- edsair.pmid.dedup....916c1190d7c5d1461cc2a860c1c732b4